seekingalpha.com · 11 jun

Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside

Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes.

fool.com · 9 jun

2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now

The shares of both stocks are down so far this year. Stevanato is benefiting from the need for GLP-1 injectables.

businesswire.com · 8 jun

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- #DiabetesTherapies--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism.

businesswire.com · 3 jun

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders (“Shareholders' Meeting”) held virtually on May 26, 2026, have passed. Details of the resolutions submitted to, and approved by, t.

zacks.com · 3 jun

Implied Volatility Surging for Stevanato Stock Options

Investors need to pay close attention to STVN stock based on the movements in the options market lately.

seekingalpha.com · 12 may

Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com · 7 may

Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript

Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript

zacks.com · 7 may

Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates

Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.11 per share a year ago.